看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。# ]$ }6 M) c! @" k
/ N! S: E @- G( a
( \6 v5 q6 f! i9 SCurrently available feasibility data for possible combination strategies. 5 Y6 z& v' j9 S$ a5 o
————————————————————————————————& I1 z0 H3 t8 L
Combination Feasibility according to preliminary data % L6 V8 L1 C3 h8 B
——————————————————————————————————1 I! P6 D0 N5 m
Bevacizumab + sorafenib Yes, reduced dose ' m+ q0 D; v' c" R
Bevacizumab + sunitinib† No 5 X5 B. w* p$ f6 F# j
Bevacizumab + temsirolimus Yes 9 i# d J% Z( m- h5 i
Bevacizumab + everolimus Yes
: I* k" j1 A A9 zSorafenib + sunitinib ? ' ^( S7 a) n5 U. _. L$ U. _4 n
Sorafenib + temsirolimus Yes, reduced dose
% v" h3 x! @$ J$ i; z0 _0 ZSorafenib + everolimus Yes, reduced dose ) |7 y z/ H$ L& d( \( k
Sunitinib + temsirolimus† No / W, E! n7 ^4 i+ _4 k4 o
Sunitinib + everolimus ? * \! x9 t8 P+ U
Temsirolimus + everolimus ? , ?* k2 m3 p/ O9 Z
————————————————————! d2 r @6 _* d( _, [4 w+ ?
†Led to US FDA warning.+ v7 T4 u! d( s7 M' b
?: As yet unattempted combination.
/ m+ ?0 C% w! p! ` |
显身卡
+ f6 r6 O8 I4 p( C% w% R
